Novartis AG to Acquire Regulus Therapeutics Inc. in a Deal Worth Up to $1.7 Billion

In a landmark deal, Novartis AG has agreed to acquire Regulus Therapeutics Inc., a move that could be worth up to $1.7 billion. This acquisition highlights Novartis' commitment to expanding its portfolio in the biopharmaceutical sector.

Deal Structure and Future Prospects

The agreement includes an initial payment of $7.00 per share, totaling $0.8 billion, with an additional $7.00 per share contingent upon the regulatory approval of Regulus' lead product candidate, farabursen. This strategic acquisition is poised to enhance Novartis' capabilities in addressing unmet medical needs.

Leadership's Vision

"We are thrilled to join forces with Novartis to potentially bring farabursen to patients suffering from ADPKD, a condition with limited treatment options," said Jay Hagan, CEO of Regulus. "Novartis' global development and commercial expertise will be instrumental in delivering this promising treatment to patients worldwide."

Closing Timeline

Pending customary closing conditions and regulatory approvals, the transaction is anticipated to conclude in the latter half of 2025, marking a significant milestone in the biopharmaceutical industry.